We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
Trial record 18 of 67 for:    "Prader-Willi syndrome"

Cortisol Activity in Patients With Prader-Willi Syndrome and Healthy Controls

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00932932
Recruitment Status : Completed
First Posted : July 7, 2009
Last Update Posted : June 27, 2011
Information provided by:

Study Description
Brief Summary:
The purpose of the study is to find out if people with Prader-Willi syndrome have a difference in the protein which changes inactive cortisone to the active stress hormone cortisol.

Condition or disease
Prader-Willi Syndrome

Study Design

Study Type : Observational
Estimated Enrollment : 36 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: 11 Beta Hydroxysteroid Dehydrogenase 1 (11-beta HSD 1) Activity in Patients With Prader-Willi Syndrome and in Healthy Controls
Study Start Date : February 2009
Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

PWS not receiving Growth Hormone
Control subjects healthy or obese
PWS subjects starting Growth Hormone

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   6 Months and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Defined population

Inclusion Criteria:

  • Prader-Willi syndrome confirmed by molecular testing, ages 6 months to adult
  • Controls: Age-matched, sex-matched, developmentally normal, BMI-controlled healthy or obese subjects

Exclusion Criteria:

  • PWS subjects without molecular confirmation of the diagnosis
  • Subjects receiving glucocorticoid treatment within 3 months of evaluation
  • Subjects receiving growth hormone within one year prior to analysis
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00932932

Sponsors and Collaborators
Children's Mercy Hospital Kansas City
Principal Investigator: Wayne Moore, MD Children's Mercy Hospital Kansas City
More Information

Responsible Party: Jill Jacobson,MD, Children's Mercy Hospitals and Clinics
ClinicalTrials.gov Identifier: NCT00932932     History of Changes
Other Study ID Numbers: 09 01-014
First Posted: July 7, 2009    Key Record Dates
Last Update Posted: June 27, 2011
Last Verified: June 2011

Additional relevant MeSH terms:
Prader-Willi Syndrome
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Nutrition Disorders